![Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.](https://oncodaily.com/pub/uploads/2023/09/Rami-e1713456764370.jpg)
Photo taken from Rami Manochakian/Twitter
Oct 4, 2023, 17:57
Rami Manochakian: Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative exclaim2 trial.
Rami Manochakian, Associate Professor and Hematology/Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:
“Hot off the press.
Takeda Oncology announced voluntary WITHDRAWAL of Mobocertinib (in the US and globally) for patients with advanced EGFR, Exon20 insertion mutation-positive non-small cell lung cancer, after negative Exclaim2 trial.”
For deteils click here.
Source: Rami Manochakian/Twitter